BlackRock introduced the iShares Nasdaq 100 ETF (IQQ), which tracks the same Nasdaq-100 index as the popular QQQ ETF but with a lower expense ratio of 0.12%, currently waived to 0.10% until July 2027. This new ETF offers cost savings compared to QQQ's 0.18% fee, making it attractive for new investors or those regularly investing in Nasdaq-100. However, existing QQQ holders may not benefit from switching due to potential tax costs outweighing fee savings. Despite cheaper alternatives, QQQ remains dominant due to its high liquidity and large options market, which benefits frequent traders and those valuing ease of trading. Investors planning long-term buy-and-hold strategies might consider IQQ or other low-fee ETFs, but for active traders or those already invested, QQQ's advantages likely outweigh its higher fees.
BlackRock's new iShares Nasdaq 100 ETF (IQQ) enters a competitive market. For readers following US technology stocks, here is Pluang's market snapshot as of Sep 22, 2026 20:03 WIB: out of 150 priced Technology-sector US stocks, 94 rose and 51 fell. Notable movers include BlackBerry Limited (BB) at USD 9.15 with a +7.27% change and a typical hold time of 50 days, Shopify Inc. (SHOP) at USD 145.50 up 5.50% with a 77-day hold, and Grab Holdings Ltd. (GRAB) at USD 3.05 rising 4.81% with a 94-day hold. Pluang order activity shows SHOP with 100% buy interest, BB with 59% buy, and GRAB with 78% buy.
MillerKnoll reported a strong Q1 2027 earnings per share (EPS) of $0.53, surpassing analyst expectations by over 51%, helped by tariff refunds and improved cost management. However, its revenue fell 3.4% year-over-year to $923.40 million, missing est...
THOR Industries reported Q4 earnings with an EPS of $0.78, missing analyst estimates and showing a 66.9% drop from last year. Despite this, the company beat revenue expectations with $2.31 billion, though revenue declined 8.4% year-over-year due to w...
Cracker Barrel Old Country Store is set to report its Q3 2026 earnings on September 23, with analysts predicting a significant decline. Earnings per share are expected to fall to $0.17 from $0.74 last year, and revenue is forecasted around $834.57 mi...
Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $...
HSBC and Wells Fargo have downgraded Netflix stock due to declining subscriber engagement and an 8% drop in viewership time. Despite a recent 2.19% stock gain, Netflix shares have fallen over 40% in the past year amid strong competition and weaker or...
